This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Objective: To investigate associations between statin (3-hxydroxy-3-methylglutaryl-coenzyme A reductase inhibitor) use and Parkinson disease (PD).
Methods: We used a population-based design to recruit 312 incident idiopathic PD cases and 342 controls from three rural California counties.
Results: We observed a higher frequency of statin use among controls vs cases (OR 0.45; 95% CI 0.29 to 0.71) and a strong dose-response relation. The strongest protective association between statin use and PD was observed in long-term (≥5 years) users (OR 0.37; 95% CI 0.18 to 0.78). There was no difference by gender or age. We noted 60 to 70% risk reductions for each individual statin except pravastatin.
Conclusion: Ascribing causality to these associations is premature and further studies are needed to confirm a potential neuroprotective role for statins in PD.
GLOSSARY: B-D test = Breslow-Day test; NO = nitric oxide; PD = Parkinson disease; PEG = Parkinson's Environment and Genes.
Footnotes
-
awahner{at}ucla.edu
e-Pub ahead of print on January 9, 2008, at www.neurology.org.
Supported by NIH—National Institute of Environmental Health Sciences Grants ES10544, U54ES12078, and pilot funding received from the SCEHSC # 5P30 ES07048, the American Parkinson Disease Association, and the SW PADRECC Veterans Administration.
Disclosure: The authors report no conflicts of interest.
Received May 7, 2007. Accepted in final form August 14, 2007.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
